RSC Bay Area Is First in the Nation to Deploy FDA-Cleared AI for Embryo Assessment by Alife Health, Pioneering a New Standard in IVF Care

RSC Bay Area, a leading US fertility practice, has become the first clinic in the U.S. to use Alife Health’s Embryo Predict for routine clinical IVF treatment.
This comes days after the AI-powered embryo assessment tool received FDA clearance, marking a substantial step in U.S. reproductive medicine.
Embryo Predict uses AI trained on thousands of embryo images to analyze blastocysts and generate a score that aids in selecting the most viable embryo for transfer, reducing subjectivity.
The tool’s approval followed a large multi-center randomized trial, which RSC Bay Area participated in and demonstrated the tool’s effectiveness.
The integration of Embryo Predict into RSC Bay Area’s practice was made possible through years of partnership and collaboration between RSC Bay Area’s parent network, US Fertility, and Alife Health.
Patients at RSC Bay Area now have access to this advanced AI-assisted embryo selection as part of their standard IVF care options.
The Embryo Predict tool has received FDA clearance in the U.S. and CE Mark in Europe, and is commercially available in the U.S., Europe, and the U.K.
Embryo Predict complements the expertise of embryologists, providing an additional data-driven insight to support consistent, evidence-based decisions in embryo selection.